Ligand Pharmaceuticals Inc: A Snapshot of Recent Performance and Company Overview

Ligand Pharmaceuticals Incorporated, a prominent player in the health care biotechnology sector, is headquartered in San Diego, United States. The company is renowned for its specialization in developing drugs that target hormone-activated intracellular receptors. These receptors are pivotal in regulating genetic processes linked to a variety of diseases, including gynecological disorders, certain cancers, cardiovascular conditions, inflammatory diseases, and skin ailments.

As of June 22, 2025, Ligand Pharmaceuticals’ stock closed at $114.98 on the Nasdaq exchange. This figure is part of a broader financial context where the company’s stock has experienced significant fluctuations over the past year. The 52-week high was recorded at $129.9 on November 6, 2024, while the 52-week low was $77.53 on June 25, 2024. These figures highlight the volatility and dynamic nature of the biotechnology sector.

Ligand Pharmaceuticals boasts a market capitalization of approximately $2.21 billion USD. However, the company’s price-to-earnings ratio stands at -16.1, indicating that it is currently not generating positive earnings. This metric is often a point of interest for investors analyzing the company’s financial health and future prospects.

Founded on November 18, 1992, Ligand Pharmaceuticals has been a significant entity in the biotechnology industry for over three decades. The company continues to focus on its core mission of developing innovative therapeutic solutions that address critical health challenges.

For more detailed information about Ligand Pharmaceuticals and its offerings, interested parties can visit their official website at www.ligand.com .